@typezerotech
Charlottesville, VA,
January 4, 2016 (Newswire.com) -
TypeZero Technologies is pleased to announce that we will provide our inControl
AP (Artificial Pancreas) diabetes management platform as the core
analytic and control technology for the NIH sponsored, $12.7 million
clinical study called the International Diabetes Closed Loop Trial
(“IDCL”). This trial is scheduled to begin in early 2016 and is managed
by Dr. Boris Kovatchev and the Center for Diabetes Technology at the University of Virginia (“UVA”).
Click the link to read the whole article.
http://www.newswire.com/news/typezero-technologies-artificial-pancreas-solution-incontrol-ap-will-be-7208527
My question about this amazing technology is will the user be able to customize the range at which this artificial pancreas will maintain a person's blood sugar? Or is this something you will not be able to adjust at all and what is the lowest a person can set to maintain?
Please leave me your comments, it helps keep me motivated!
TypeZero Technologies' Artificial Pancreas Solution, inControl AP, Will Be Tested in a Large Scale, NIH Funded ($12.7 Million) Clinical Study Run by the University of Virginia and 8 Other Locations in 2016
TypeZero's inControl AP platform will revolutionize diabetes management for many Type 1 patients around the world.
Click the link to read the whole article.
http://www.newswire.com/news/typezero-technologies-artificial-pancreas-solution-incontrol-ap-will-be-7208527
My question about this amazing technology is will the user be able to customize the range at which this artificial pancreas will maintain a person's blood sugar? Or is this something you will not be able to adjust at all and what is the lowest a person can set to maintain?
Please leave me your comments, it helps keep me motivated!
No comments:
Post a Comment
➼ Please leave a comment, help keep me motivated to blog. Your email address will not be published and you will not receive any spam. Any comments with links or spam will not be published so do not waste your time.